Product Profile

Mechanism of Action (MoA)

AGAcell® works through several complementary mechanisms:

  • Paracrine signaling: counteracts follicle miniaturization.
  • Energy co-factor (ATP): potentiates MSC activity.
  • Restoration of the hair follicle niche microenvironment

Formulation and Administration

Formulation

  • Cell suspension for intradermal injection: 1×10⁶ cells/mL + ATP.
  • Ready-to-use kit, store at 2–8 °C, do not freeze.

Dose & Administration

  • Recommended: 1×10⁵ cells/cm²
  • Treatment área: 30–150 cm² (Norwood III–V).
  • Administration: single intradermal (scalp) injection.

Kit & conditioning

  • 3–15 prefilled 1 mL syringes (area-adjusted). 2–8 °C; do not freeze; single‑use.
  • shelf life: 96 h from batch release.

Project Pipeline

Project​

Area

Pathology

Type of Cell​

Cellular Source​

IP​

Preclinical​

Phase I​

Phase IIa and Phase IIb

Phase III

MA

Dermatology

AGA


Mesenchymal stem cells


Allogenic


WO/2025/133317

Browse through our resources​

AGACell’s Principal Investigator, Dr. López Bran, Participates as a Speaker at the FUE ASIA Congress

Hair transplantation: effective and safe, without medication

The end of baldness in Spain? A nurse reveals a study with ‘very promising’ results.

Entrepreneurship in Biotechnology: Leading with a Vision for the Next Decade

Marisa Berenguer, CEO of Ideeea Therapeutics: “AGAcell is the first proposal to combine allogeneic mesenchymal stem cells from a healthy external donor to treat androgenetic alopecia.”

Mesenchymal stem cells and regeneration

Ideeea Therapeutics Selected Among the TOP15 Startups Transforming Spanish Biotechnology

ASEME honors Marisa Berenguer, CEO of Ideeea Therapeutics, for leading a pioneering biotechnology project

ASEME honors Marisa Berenguer, CEO of Ideeea Therapeutics, for leading a pioneering biotechnology project

ASEME honors Marisa Berenguer, CEO of Ideeea Therapeutics, for leading a pioneering biotechnology project

ASEME premia a Marisa Berenguer, CEO de Ideeea Therapeutics, por liderar un proyecto biotecnológico pionero

Ageing and Androgenetic Alopecia (AGA)

Habits and androgenetic alopecia

The Market for Alopecia Treatments and the Promise of Advanced Therapies

Androgenetic Alopecia and Mental Health

Androgenic alopecia: conventional treatment options and innovative approaches

Melanoma and androgenetic alopecia

AGAcell® on «La Vanguardia»: Ideeea Therapeutics’ Bet on Androgenetic Alopecia

AGAcell® on «Tele 5»: Closer to ending alopecia: Spanish stem cell research could be the solution

AGAcell® on «20 minutos»: A Spanish stem cell study brings the end of alopecia closer.

AGAcell® on «La Razón»: A Spanish hospital uses stem cells to treat alopecia

AGAcell® on «El Español»:In four years, we could have a stem cell therapy to end baldness.

AGAcell® on «Antena 3»:Is the end of baldness near? This Spanish stem cell treatment has worked successfully in mice

AGAcell® on «RTVE»:A Spanish Study Brings the End of Alopecia Closer

«Europapress»: Ideeea Tx announces AGAcell, a preclinical investigational cell therapy program for alopecia

«El Confidencial»: Ideeea Therapeutics announces AGAcell®: An allogeneic cell therapy program in preclinical development for alopecia.

AGAcell® on «National Geographic»: Spanish researchers make a groundbreaking advance in the fight against alopecia

Ideeea TX on «Expansión»: Ideeea TX secures €2.3 million in funding to address alopecia through stem cell-based therapy.

«Hair growth stimulated by allogenic adipose‑derived stem cells supplemented with ATP in a mouse model of dihydrotestosterone‑induced androgenetic alopecia. López Bran et al. Stem Cell Research & Therapy volume 16, Article number: 292 (2025)

«Clinical and preclinical approach in AGA treatment: a review of current and new therapies in the regenerative field»

AGAcell® on «La Sexta»: Ideeea Therapeutics’ Bet on Androgenetic Alopecia

Shedding light on alopecia: essential facts about hair growth, causes and types